Market Malaise, Q2 Financials Weigh on Genomic Tool Vendors' Stocks in July

The GWDN Index was down 8 percent for the month as a few of the industry's better-known players surprised investors with either disappointing Q2 results or expectations of slower growth for the rest of the year.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.